Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | HTR2C | P28335 | 4/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4521825 | 0.98 | HTR2A (0.39) | HTR2AHTR2CCHEK1CCNA2CDK2 | |
| SCHEMBL2286418 | 0.90 | USP7 (0.41) | HTR2AHTR2CMAP4K4 | |
| SCHEMBL12649137 | 0.82 | CHRNB2 (0.37) | MAP4K4 | |
| Hydrochloric Acid SCHEMBL1769238 | 0.80 | CHRNB2 (0.36) | MAP4K4 | |
| SCHEMBL13282089 | 0.80 | POLB (0.43) | MAP4K4 | |
| SCHEMBL15934131 | 0.80 | POLB (0.47) | MAP4K4 | |
| SCHEMBL13522013 | 0.80 | HTR2A (0.41) | HTR2ACHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL13246579 | 0.79 | USP7 (0.50) | HTR2CMAP4K4 | |
| Hydrochloric Acid SCHEMBL4229174 | 0.79 | GRM5 (0.40) | CHEK1CCNA2CDK2CCNA1 | |
| Hydrochloric Acid SCHEMBL9054801 | 0.78 | HTR2A (0.40) | HTR2ACHEK1CCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013178591-A1 | AMINOQUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-05 | — | — | WO | disclosed |
| US-8163775-B2 | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2012-04-24 | — | — | US | disclosed |
| US-20120022108-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-01-26 | — | — | US | disclosed |
| US-8030331-B2 | Allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2011-10-04 | — | — | US | disclosed |
| US-20110112143-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-05-12 | — | — | US | disclosed |
| US-7834035-B2 | Schizophrenia and related disorders; positive allosteric modulators of mGluR5; {3-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-phenyl-methanone for example; compounds are all contain a 5-(1-carbonylpiperidin-3-yl)-1,2,4-oxadiazole moiety | ADDEX PHARMA SA (CH) | 2010-11-16 | — | — | US | disclosed |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | NIKEM RESEARCH SRL (IT) | 2009-08-27 | — | — | US | disclosed |
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | ADDEX PHARMA SA (CH) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219187-A1 | Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM2, GRM1 | HTR2A 249/4885HTR2C 345/4885CHEK1 4375/4885 |
| US-20120022108-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | HTR2A 249/4885HTR2C 345/4885CHEK1 4375/4885 |
| US-20110112143-A1 | ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | HTR2A 249/4885HTR2C 345/4885CHEK1 4375/4885 |
| US-20090215822-A1 | Substituted Oxadiazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate Receptors | GRM5, GRM3, GRM2 | HTR2A 357/4885HTR2C 288/4885CHEK1 4083/4885 |
| US-20090264425-A1 | CHEMICAL COMPOUNDS | POLR2E, POLR2A, POLRMT | HTR2A 3747/4885HTR2C 3342/4885CHEK1 3380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.